The Lynx Group
Cholangiocarcinoma News

Phase 2 Study of Nivolumab with Gemcitabine/Cisplatin or Ipilimumab as First-Line Therapy for Patients with Advanced Unresectable BTC (BilT-01)

Web Exclusives — May 30, 2020

This randomized, phase 2 multi-institutional study was designed to investigate the role of combinational immunotherapy, using nivolumab with gemcitabine/cisplatin, or nivolumab with ipilimumab in patients with untreated advanced biliary tract cancer.1

Arm A included gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on days 1 and 8 every 3 weeks plus nivolumab 360 mg on day 1 every 3 weeks for 6 months followed by nivolumab 240 mg every 2 weeks as monotherapy for a total duration of 2 years; arm B included nivolumab 240 mg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks for 2 years, in the absence of disease progression. The primary end point was progression-free survival (PFS) at 6 months. Secondary end points included best overall response rate per immune-related RECIST, median PFS, overall survival, and safety. Exploratory objectives included biomarker analysis using sequential whole exome/transcriptome and immune cell subsets in tissue and blood.

A total of 64 eligible patients were enrolled: 32 in arm A and 32 in arm B, with a median age of 62 years (range, 20-80 years), and 90% with metastatic disease. PFS at 6 months was 64.2% in arm A and 23.4% in arm B. Median PFS was 7.4 months in arm A and 4.1 months in arm B. Median overall survival was 10.6 in arm A and 8.3 in arm B. Whereas PFS in arm B was inferior to historical controls, arm A appeared to be as effective as standard-of-care chemotherapy. A total of 40% of patients in arm A are still alive, which suggests that there may be a “tail” on the survival curve. Analyses are still pending for safety and toxicity, overall response rate, genomic analysis, and immune subset analysis.

Although arm A was not superior to standard-of-care chemotherapy, there are 2 phase 3 trials currently open globally that are accruing patients (NCT04003636 and NCT03875235). ClinicalTrials.gov number NCT03101566.

Reference

  1. Sahai V, et al. ASCO 2020. Abstract 4582.

Related Items

The Latest Research in Biliary Tract Cancers Presented at ASCO GI 2021
March 2021, Vol 2, No 1
At the CCA Summit held during the 2021 ASCO Gastrointestinal (GI) Cancers Symposium, Rachna T. Shroff, MD, MS, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, Tucson, discussed 15 clinical trials that were presented at the ASCO GI Cancers Symposium on cholangiocarcinoma (CCA) and hepatobiliary diseases. She highlighted key advances related to chemotherapy, targeted therapies, and biomarkers in the management of biliary tract cancers, including CCA.
Zanidatamab Addresses an Unmet Need in Patients with HER2-Amplified Biliary Tract Cancer
December 2020, Vol 1, No 3
Patients with relapsed or refractory HER2-amplified biliary tract cancer have few treatment options after first-line therapy. Shubham Pant, MD, Associate Professor, Gastrointestinal Oncology, M.D. Anderson Cancer Center, Houston, TX, presented the results of a phase 1 clinical trial he and his colleagues conducted. The study examined the safety and antitumor activity of zanidatamab, a bispecific (ie, binding to 2 distinct sites on the HER2 receptor) HER2-targeted antibody. The unique antibody geometry of zanidatamab enables it to activate several mechanisms of action after binding to the HER2 receptor.
Telotristat Ethyl and First-Line Chemotherapy Combination Investigated for Advanced Biliary Tract Cancer
December 2020, Vol 1, No 3
The metabolism of serotonin is dysregulated in cholangiocarcinoma (CCA) cell lines compared with normal cholangiocytes and in tissue and bile from patients with CCA.1 Telotristat ethyl (Xermelo) is a tryptophan hydroxylase inhibitor that is indicated for the treatment of patients with carcinoid syndrome–related diarrhea not well-controlled by somatostatin analog. Telotristat ethyl is currently being investigated for the treatment of patients with biliary tract cancer, including CCA tumors that express serotonin.
The Khorana Score Not Predictive of Thrombotic Events in Patients with Biliary Tract Cancer
December 2020, Vol 1, No 3
Cancer-related venous thromboembolism (VTE) is a significant cause of morbidity and mortality. There is a paucity of studies characterizing VTE in patients with biliary tract cancer; however, a few retrospective analyses suggest an incidence of VTE of up to 23%.
Benefits of Lenvatinib plus Pembrolizumab in Solid Tumors, Including Biliary Tract Cancer
2020 Year in Review: Cholangiocarcinoma
First results of the multicohort phase 2 LEAP-005 study suggest that lenvatinib plus pembrolizumab combination immunotherapy has promising antitumor activity in patients with biliary tract cancer.
NTRK Gene Fusions in Biliary Tract Cancers
2020 Year in Review: Cholangiocarcinoma
Molecular analyses of biliary tract cancers indicate that neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare, suggesting that it is not a major driver of BTC pathogenesis.
The Worldwide Incidence of Biliary Tract Cancer
2020 Year in Review: Cholangiocarcinoma
Assessment of global epidemiologic trends in incidence of biliary tract cancers (BTCs) showed higher BTC incidence in Asian versus Western countries as well as intraregional variations within countries, which is consistent with previous reports.
Capecitabine and Cisplatin as Second-Line Chemotherapy for Patients with Advanced Biliary Tract Cancer
2020 Year in Review: Cholangiocarcinoma
Retrospective analysis data suggest that second-line chemotherapy of capecitabine and cisplatin combination therapy was associated with modest efficacy in patients with advanced biliary tract cancer.
Combination Immunotherapy with Ipilimumab and Nivolumab Shows Activity in Patients with Advanced Biliary Tract Cancer
2020 Year in Review: Cholangiocarcinoma
Preliminary data suggest that dual blockade with ipilimumab and nivolumab might have antitumor activity in a subset of patients with microsatellite-stable biliary tract cancer.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to recieve the free CCA News print publication or weekly e‑Newsletter.

I'd like to recieve: